The United States Equestrian Federation (USEF) announced today that Luitpold Animal Health, the manufacturers of Adequan® i.m. (polysulfated glycosaminoglycan), will be the title sponsor of the 2014 U.S. Reining Team, set to compete at this year's Alltech FEI World Equestrian Games, August 23 through September 7, in Normandy, France.
Reining - A rigorous horse competition
Due to the rigors of competition, many performance horses suffer from joint disease. Adequan® i.m. is designed to help treat the underlying cause of the problem and break the cycle of damage, while reducing pain and inflammation.
Luitpold Animal Health will also provide Adequan® i.m. for all eight disciplines and the horses competing for Team USA in the 2014 WEG.
"The United States Equestrian Federation is honored that Luitpold Animal Health has chosen to sponsor the 2014 Adequan® U.S. Reining Team and supply product for the entire U.S. Team," said USEF CEO Chris Welton. "Adequan® i.m. has a long track record of safety and strong efficacy in the treatment of equine joints. We could not think of a better partner than Luitpold Animal Health and look forward to and appreciate their continued support of the USEF."
The partnership marks the third consecutive Alltech FEI World Equestrian Games that Adequan® will be the title sponsor of the U.S. Reining Team. The 2014 Adequan® U.S. Reining Team will look for a repeat showing of the 2010 Team’s spectacular performance at the WEG, when it won the Team Gold medal.
The 2010 Adequan® U.S. Reining Team of Tim McQuay, Criag Schmersal, Tom McCutcheon and Shawn Flarida all gave electric rides to take the U.S. to a large winning margin.
“We have been very fortunate to have had the 2006 Aachen U.S. Reining Team and the 2010 Lexington, KY U.S. Reining Team wear the Adequan® brand,” states Allyn Mann, Director of Global Sales at Luitpold Animal Health. “Both teams won the Gold Medal as well as individual Silver and Bronze medals in Aachen and individual Gold and Silver medals in Lexington.”
The 2014 U.S. Reining Team competing in Normandy, France this year includes Shawn Flarida, Andrea Fappani, Jordan Larson, Mandy McCutcheon, Tom McCutcheon and Tom Heikes. The Team veterinarian, Dr. John Newcomb and the Chef d’Equipe, Jeff Petska, have been involved with the U.S. Reining Teams competing at the World Equestrian Games since Reining was introduced as a WEG Discipline at the games in 2002 in Spain.
Due to the rigors of competition, many performance horses suffer from joint disease. Adequan® i.m. is designed to help treat the underlying cause of the problem and break the cycle of damage, while reducing pain and inflammation. There is only one FDA approved source of this active ingredient, polysulfated glycosaminoglycan and it is available as Adequan® i.m.
Remember, there is no generic Adequan® i.m.
Adequan® i.m. Brief Summary:
For the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. There are no known contraindications to the use of intramuscular Adequan® i.m. brand Polysulfated Glycosaminoglycan in horses. Studies have not been conducted to establish safety in breeding horses. Each 5 mL contains 500 mg Polysulfated Glycosaminoglycan. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.